FL-501
(NBL-016)
Anti-GDF15 antibody
![](https://www.leaptx.com/wp-content/uploads/2023/03/501.png)
FL-501 is a potential best in class antibody designed to neutralize GDF15 and prevent the binding to its receptor. FL-501 was engineered to have high affinity with improved half-life compared to other molecules of its class, which may result in significantly less frequent dosing. In pre-clinical models of cachexia increases in body weight have been observed following administration of the antibody.
In addition, FL-501 is expected to inhibit the activity of GDF15 in promoting an immunosuppressive tumor micro-environment in a broad range of cancers, including gastric, colorectal, pancreatic and prostate, where elevated GDF15 also correlates with poor prognosis.
![](https://www.leaptx.com/wp-content/uploads/2023/03/diagram-img-11@2x.jpg)
GDF15 is secreted to blood stream at elevated levels
![](https://www.leaptx.com/wp-content/uploads/2023/03/diagram-img-09@2x.jpg)
GDF15 overexpression leads to Cachexia
- Nausea
- Loss of
appetite - Decreased
weight - Lower muscle
mass
![](https://www.leaptx.com/wp-content/uploads/2023/03/diagram-img-10@2x.jpg)
FL-501 prevents GDF15 from binding to GFRAL
- Normal
appetite - Normal
weight - Normal
muscle mass